Aryl debromination acylation method for bromo-benzo nitrogen heterocyclic compound

Through microchannel continuous flow reaction technology, the preparation process of acylbenzoazole heterocyclic compounds is simplified, the problems of harsh reaction conditions and cumbersome steps in the existing technology are solved, and the efficient and low-cost acylization process is realized, which is suitable for large-scale Production.

CN119059958APending Publication Date: 2024-12-03SHANGHAI WOKAI BIOTECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411176905.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The preparation method of acyl-substituted benzoazole heterocyclic compounds in the prior art has harsh reaction conditions, complicated steps, high production costs, and raw materials and products need pretreatment or post-treatment, making it difficult to carry out large-scale production.

Method used

Using microchannel continuous flow reaction technology, the active hydrogen in the brominated benzoazane heterocycle is extracted by amino alkyl silane compounds, and then the bromine is removed using lithium alkyl, and finally reacted with amide compounds to achieve acylation, simplifying the steps and reduce the reaction conditions.

Benefits of technology

It realizes the efficient preparation of acyl benzoazole heterocyclic compounds under mild conditions, simplifies the process flow, improves yield and purity, and is suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119059958A_ABST
    Figure CN119059958A_ABST
Patent Text Reader

Abstract

The invention relates to the field of compound synthesis, in particular to an aryl debromination acylation method of a bromo-benzo nitrogen heterocyclic compound, which comprises the following steps: mixing a solution containing the bromo-benzo nitrogen heterocyclic compound with a solution containing a hydrogen pulling reagent to carry out first reaction, and pulling out reactive hydrogen on nitrogen heterocyclic ring to obtain a first material; mixing with a solution containing a debromination reagent for a second reaction to obtain a second material, carrying out a third reaction on the second material and a solution containing an amide compound, carrying out a nucleophilic substitution reaction on a substitution position of original bromine on aryl of the bromo-benzo-nitrogen heterocyclic compound to obtain an acylated substituent group, and quenching after the reaction is completed to obtain the bromo-benzo-nitrogen heterocyclic compound. And carrying out post-treatment to obtain the acylated substituted benzo nitrogen heterocyclic compound. Wherein the brominated benzo nitrogen heterocyclic compound is selected from one of a brominated indole compound, a brominated benzimidazole compound, a brominated indazole compound, a brominated indoline compound and a brominated carbazole compound; the method is mild in condition, and the product yield is more than 80%.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of compound synthesis, and in particular to a method for debromination and acylation of aromatic groups of brominated benzazazepine heterocyclic compounds. Background Art

[0002] Benzene nitrogen heterocyclic compounds are an important fine chemical raw material, which are widely present in nature. Due to their unique chemical structure and biological activity, they are widely used in pesticides, medicines, spices, dyes, feeds, foods and additives. Therefore, the synthesis and preparation of benzene nitrogen heterocyclic compounds have always attracted extensive attention and research. Among the many synthetic methods, direct conversion through functional groups is one of the most effective methods. Among them, acyl groups are highly active conversion groups, which can be more easily converted into other functional groups. Therefore, acyl-substituted benzene nitrogen heterocyclic compounds are often used as starting materials for the synthesis of pharmaceutical intermediates and APIs. For example, indole-5-carboxaldehyde obtained by replacing the C5 position of the indole aryl with a formyl group is an important raw material for preparing the migraine drug Naratriptan. In addition, it can also be used to prepare 5-piperazinemethyl-N1-arylsulfonyl indole, which can be used as a 5-HT 6R ligand and is a potential drug precursor for the treatment of schizophrenia and Alzheimer's disease [ACS Med. Chem. Lett. 2010, 1, 340-344]. Therefore, the development of an industrial synthesis process for formyl-substituted benzazazepine heterocyclic compounds is of great significance.

[0003] At present, the preparation method of acyl-substituted benzazazolyl heterocyclic compounds is mainly to extract hydrogen from the corresponding bromide under heating and reflux in a strong base sodium amide to obtain a sodium salt intermediate, then extract the bromine with tert-butyl lithium and react with a nucleophilic reagent to finally obtain an aromatic substituted indole derivative through a two-step one-pot method [J.Org.Chem.1986,51(26):5106-5110]. This method has relatively harsh reaction conditions and can only be completed at -78°C in anhydrous and oxygen-free conditions, making it difficult to produce on a large scale.

[0004] In addition to bromobenzazaheterocyclic compounds as raw materials, N-Boc benzazazaheterocyclic compounds substituted with boric acid can be reacted with tetrahydroquinoline as a catalyst and formylformic acid as an acylating agent at room temperature for 36 hours to obtain aromatic substituted indole derivatives substituted with N by Boc. This method has mild conditions, but the reaction time is long and the reaction yield is low. In addition, the reaction raw materials need to be pre-prepared and the product needs to be deprotected to obtain the final indole-5-carboxaldehyde product, which increases the difficulty of the reaction process and post-treatment process, and the reaction yield is low [Angew.Chem.2017,129,8313–8317].

[0005] In the above methods, the reaction conditions are either harsh, the steps are complicated and the production cost is high, or both the reaction raw materials and the products need to be pre-treated or post-treated, resulting in low yields. Therefore, it is difficult to carry out large-scale production. Summary of the invention

[0006] In view of the above technical defects, a method for debromination and acylation of the aromatic group of a brominated benzazazepamocyclic compound is provided. The method of the invention is simple to operate, has simple raw materials, high yield, is easy to post-process, and is suitable for industrial large-scale production, and can efficiently prepare acylbenzazepamocyclic compounds.

[0007] In order to achieve the above objectives, the present invention is implemented by the following technical solutions:

[0008] The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound comprises the following steps:

[0009] S1, mixing a solution containing a brominated benzene nitrogen heterocyclic compound with a solution containing a hydrogen extraction agent to perform a first reaction to remove active hydrogen from the nitrogen heterocyclic ring to obtain a first material;

[0010] S2, mixing the first material with a solution containing a debromination agent to perform a second reaction to obtain a second material;

[0011] S3, allowing the second material to undergo a third reaction with a solution containing an amide compound, so that a nucleophilic substitution reaction occurs at the substitution position of the original bromine on the aromatic group of the brominated benzazazepine heterocyclic compound to obtain an acylated substituent, and after the reaction is completed, the reaction is quenched, and post-processing is performed to obtain an acylated substituted benzazazepine heterocyclic compound;

[0012] The brominated benzazazepine heterocyclic compound is selected from the group consisting of brominated indole compounds, brominated benzimidazole compounds, brominated indazole compounds, brominated indoleline compounds, and brominated carbazole compounds;

[0013] The hydrogen-extraction reagent is an aminoalkylsilane compound; and the debromination reagent is a C1-C20 normal or isomeric alkyl lithium.

[0014] Furthermore, the brominated benzazazepine heterocyclic compound has the following chemical structure:

[0015]

[0016] Wherein, X is selected from nitrogen atom or carbon atom; when X is nitrogen atom, R1 is absent; when X is carbon atom, R1 is selected from hydrogen atom, C1-C6 normal or isomeric alkyl, chlorine atom; R5 is selected from halogen atom, such as fluorine atom;

[0017] R2 and R3 are each selected from a hydrogen atom, a C1-C6 normal or isomeric alkoxy group, or a C1-C6 normal or isomeric alkyl group, and R2 and R3 are the same or different;

[0018] R4 is selected from a hydrogen atom, a C1-C6 normal or isomeric alkoxy group;

[0019] R6 and R7 are each selected from a hydrogen atom, a C1-C6 normal or isomeric alkyl group, and R6 and R7 are the same or different;

[0020] The aminoalkylsilane compound is selected from sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, and lithium bis(trimethylsilyl)amide;

[0021] The alkyl lithium is n-butyl lithium;

[0022] The amide compound is selected from one of N,N-dimethylformamide, N,N-dimethylacetamide, N-methoxy-N-methyl-benzamide, N-methoxy-N-methyl-acetamide, and N-methyl-N-methoxy-[(2S)-O-(tert-butyldimethylsilyl)-N'-(ethoxyformyl)]propionamide.

[0023] Further, the brominated benzazazepine heterocyclic compound is selected from 4-bromoindole, 5-bromoindole, 6-bromoindole, 7-bromoindole, 6-fluoro-5-bromoindole, 7-fluoro-6-bromoindole, 3-methyl-7-bromoindole, 3-ethyl-7-bromoindole, 3-chloro-7-bromoindole, 3-chloro-5-bromoindole, 3-bromocarbazole, 8-methoxy-3-bromocarbazole, 1-methyl-3-bromo-carbazole, 1,7-dimethyl-3-bromo-carbazole, 1,6-dimethyl-3-bromo-carbazole, 7-methoxy-3-bromo-carbazole, 3-bromo-6-methoxy-carbazole, 6,7-dimethoxy-3-bromo-carbazole, 4-bromobenzimidazole, 5-bromobenzimidazole, 7-bromo-indazole, 5-bromo-indoline, and 5-bromo-2-oxoindoline.

[0024] Furthermore, the first reaction is carried out in a first group of microchannel continuous flow reactors, the second reaction is carried out in a second group of microchannel continuous flow reactors, and the third reaction is carried out in a third group of microchannel continuous flow reactors; the first group of microchannel continuous flow reactors, the second group of microchannel continuous flow reactors, and the third group of microchannel continuous flow reactors are connected to each other by microchannels; and each raw material is pumped into the reactor of each reaction stage in an injection pump.

[0025] Furthermore, the first group of microchannel continuous flow reactors consists of three glass chips, the second group of microchannel continuous flow reactors consists of five glass chips, and the third group of microchannel continuous flow reactors consists of two glass chips, and each glass chip has a liquid holding capacity of 20 mL.

[0026] Furthermore, the reaction temperature of the first reaction is in the range of 23°C-65°C, and the residence time is in the range of 100 seconds-200 seconds; the reaction temperature of the second reaction is in the range of minus 35°C-minus 10°C, and the residence time is in the range of 80 seconds-180 seconds; the reaction temperature of the third reaction is in the range of 12°C-50°C, and the residence time is in the range of 30 seconds-55 seconds.

[0027] Preferably, the reaction temperature of the first reaction is 25°C-60°C, and the residence time is 120 seconds-180 seconds; the reaction temperature of the second reaction is minus 30°C-minus 20°C, and the residence time is 100 seconds-150 seconds; the reaction temperature of the third reaction is 15°C-45°C, and the residence time is 35 seconds-50 seconds.

[0028] Furthermore, the molar ratio of the brominated benzazazepine heterocyclic compound, the hydrogenation reagent, the debromination reagent, and the amide compound is 1:1:2:2-4.

[0029] Furthermore, the solvents in the solution containing brominated benzazazepine heterocyclic compounds, the solution containing hydrogen extraction reagents, the solution containing debromination reagents, and the solution containing amide compounds are respectively anhydrous tetrahydrofuran or n-hexane;

[0030] The concentration of the solution containing the brominated benzazine heterocyclic compound is 0.8-1.5 mol / L, and the flow rate in the reactor is 10-30 mL / min;

[0031] The concentration of the solution containing the hydrogen extraction agent is 0.8-2 mol / L, and the flow rate in the reactor is 20-40 mL / min;

[0032] The concentration of the solution containing the debromination agent is 0.8-2 mol / L, and the flow rate in the reactor is 20-40 mL / min;

[0033] The concentration of the solution containing amide compounds is 1.5-5 mol / L, and the flow rate in the reactor is 10-30 mL / min.

[0034] Furthermore, the post-treatment includes the following operations: cooling the third material collected from the third group of microchannel continuous flow reactors to below 5°C, adding aqueous phosphoric acid solution to quench the reaction, extracting with an acid ester solvent, combining the organic phases, washing, drying, desolventizing, and recrystallizing.

[0035] Beneficial technical effects:

[0036] The present invention develops a method for introducing an acyl group on the benzene ring of a brominated benzazazepine heterocyclic compound, and efficiently realizes the synthesis of the acyl benzazazepine heterocyclic compound through a microchannel continuous flow technology; an organic base (such as sodium di(trimethylsilyl)amide HMDSNa) is used as a hydrogen extraction reagent to remove the active hydrogen on the nitrogen heterocyclic N atom in the brominated benzazazepine heterocyclic compound, and then an alkyl lithium is used as a debromination reagent to remove the bromine on the benzene ring, and then reacts with an amide compound in a microchannel, so that the reaction conditions can be milder and do not need to reach minus 78° C. in conventional technology; the intermediate product in the reaction process does not need to be separated and directly enters the next step of reaction, and after the reaction is completed, only simple quenching and extraction are required to obtain a high-purity acyl benzazazepine heterocyclic compound;

[0037] The reaction conditions of the invention are relatively mild, the raw materials are simple, the yield is high, the purity is good, the reaction can be continuously scaled up for production, less "three wastes" are generated, the process is green and environmentally friendly, and the process is suitable for industrial large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 Schematic diagram of the microchannel continuous flow process for preparing indole-5-carboxaldehyde. DETAILED DESCRIPTION

[0039] The technical solutions in the embodiments of the present invention will be described clearly and completely below in combination with the embodiments of the present invention and the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. The following description of at least one exemplary embodiment is actually only illustrative and is by no means intended to limit the present invention and its application or use. All other embodiments obtained by ordinary technicians in this field without creative work based on the embodiments of the present invention are within the scope of protection of the present invention.

[0040] Unless otherwise specifically stated, the numerical value set forth in these embodiments does not limit the scope of the present invention. The technology and method known to those of ordinary skill in the relevant art may not be discussed in detail, but in appropriate cases, the technology and method should be considered as a part of the specification. In all examples shown and discussed here, any specific value should be interpreted as being merely exemplary, rather than as a limitation. Therefore, other examples of exemplary embodiments may have different values.

[0041] In addition, it should be noted that the use of words such as "first" and "second" to limit reaction temperature, microchannel continuous flow reactor, etc. is only to facilitate the distinction between the reaction steps. Unless otherwise stated, the above words have no special meaning and therefore cannot be understood as limiting the scope of protection of the present invention.

[0042] The experimental methods in the following examples without specifying specific conditions are usually measured in accordance with national standards; if there is no corresponding national standard, the method is carried out in accordance with the general standard requirements or general methods.

[0043] The yields described below are product by mass, in the unit of wt%, and wt will be omitted below.

[0044] Residence time refers to the time required for the material to pass through the microchannel continuous flow reactor, and the specific calculation method is: residence time = liquid holding volume × (60s / min) / total volume flow rate;

[0045] The holdup volume is the capacity of the microchannel continuous flow reactor, and the holdup of a single glass core is a fixed value of 20 mL;

[0046] The total volumetric flow rate is the sum of the individual syringe pump flow rates.

[0047] Example 1

[0048] Conventional method for preparing indole-5-carboxaldehyde:

[0049] Add 5-bromoindole (19.6 g, 0.1 mol) to a 500 mL three-necked flask, add 100 ml of anhydrous tetrahydrofuran under nitrogen protection, stir until 5-bromoindole is completely dissolved, add sodium bis(trimethylsilyl)amide (100 mL, 1 M, tetrahydrofuran solution), and continue stirring at room temperature for 1 hour. Then cool the reaction solution to -78 °C, slowly add n-butyl lithium solution (125 mL, 1.6 M, n-hexane solution), and continue stirring for 1 hour after the addition is complete. Finally, add N,N-dimethylformamide (DMF, 0.2 mol, 15.5 mL dissolved in 85 mL tetrahydrofuran solution), raise the reaction temperature to room temperature, continue stirring, and detect by TLC spot plate until the reaction is complete. Stop the reaction, cool the reaction mixture to 0°C, slowly add 1M H3PO4 aqueous solution to quench the reaction, and extract with ethyl acetate. Combine the organic phases, wash with saturated NaHCO3 aqueous solution, dry over anhydrous MgSO4, and rotary evaporate to obtain a crude product. Recrystallize from ethanol to obtain indole-5-carboxaldehyde with a yield of 89 wt%.

[0050] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows:

[0051] 1 H NMR (400MHz, CDCl3) δ10.04(s,1H),8.53(s,1H),8.19(s,1H),7.79(dd,J=8 .5,1.5Hz,1H),7.49(d,J=8.5Hz,1H),7.35–7.30(m,1H),6.74–6.69(m,1H);

[0052] 13 C NMR (101MHz, CDCl3) δ192.74,139.37,129.78,127.74,126.38,126.10,122.31,111.76,104.50.

[0053] Example 2

[0054] A method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound, specifically a microchannel continuous flow method for preparing indole-5-carboxaldehyde, the process flow is shown in Figure 1 , including the following steps:

[0055] S1. Preparation of 5-bromoindole solution: Add 5-bromoindole (raw material, 19.6 g, 0.1 mol) into a 500 mL three-necked flask, add 80 mL of anhydrous tetrahydrofuran under nitrogen protection, and stir until 5-bromoindole is completely dissolved;

[0056] Sodium bis(trimethylsilyl)amide solution (base, HMDSNa, 100mL, 1M tetrahydrofuran solution) and 5-bromoindole solution (100mL, 1M tetrahydrofuran solution) are introduced into the first group of microchannel continuous flow reactors ③ by syringe pumps ① and ②, respectively, and the flow rate is set to 10mL / min (or sodium bis(trimethylsilyl)amide solution is added to 5-bromoindole tetrahydrofuran solution, mixed evenly, and introduced into the first group of microchannel continuous flow reactors ③ by a syringe pump, and the flow rate is set to 20mL / min). The mixed material of the two undergoes a first reaction in the first group of microchannel continuous flow reactors ③, the temperature of the first group of microchannel continuous flow reactors ③ is set to 25°C, the retention time of the mixed material therein is 3min, and the first material is obtained by flowing out of the first group of microchannel continuous flow reactors ③.

[0057] S2, n-butyl lithium diluted solution: cool the n-butyl lithium solution (nBuLi, 125 mL, 1.6 M n-hexane solution) to -20°C, add 75 mL of anhydrous tetrahydrofuran solution to obtain a 1 M n-butyl lithium diluted solution;

[0058] The above-mentioned first material and the dilute n-butyl lithium solution entering through the injection pump ④ are simultaneously introduced into the second group of microchannel continuous flow reactor ⑤ to form a mixed material for the second reaction. The flow rate of the dilute n-butyl lithium solution is set to 20 mL / min, the temperature of the second group of microchannel continuous flow reactor ⑤ is set to -20°C, the retention time of the mixed material in the second group of microchannel continuous flow reactor ⑤ is 2.5 min, and the second material is obtained by flowing out of the second group of microchannel continuous flow reactor ⑤.

[0059] S3, DMF solution preparation: anhydrous DMF (nucleophile, 15.5 mL, 0.2 mol) was dissolved in 85 mL anhydrous tetrahydrofuran solution, mixed evenly, and a 2 M DMF tetrahydrofuran solution was prepared;

[0060] The above-mentioned second material and the DMF solution entering through the injection pump ⑥ are simultaneously introduced into the second group of microchannel continuous flow reactor ⑦ to form a mixed material for the third reaction. The flow rate of the DMF solution is set to 10 mL / min, the temperature of the third group of microchannel continuous flow reactor ⑦ is set to 25°C, the retention time of the mixed material in the third group of microchannel continuous flow reactor ⑦ is 48s, and the third material is obtained by flowing out from the third group of microchannel continuous flow reactor ⑦ and collecting.

[0061] Post-treatment: The third material was cooled to 0°C, 1M H3PO4 aqueous solution was slowly added to quench the reaction, and extracted with ethyl acetate. The organic phases were combined, washed with saturated NaHCO3 aqueous solution, dried over anhydrous MgSO4, and the solvent was removed by distillation under reduced pressure to obtain a crude product, which was recrystallized from ethanol to obtain refined indole-5-carboxaldehyde.

[0062] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0063] Example 3

[0064] This case specifically involves the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the first group of microchannel continuous flow reactors ③ is set to 40°C.

[0065] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0066] Example 4

[0067] This case is specifically about preparing indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the first group of microchannel continuous flow reactors ③ is set to 60°C.

[0068] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0069] Example 5

[0070] This case is specifically about preparing indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the second group of microchannel continuous flow reactors ⑤ is set to -30°C.

[0071] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0072] Example 6

[0073] This case specifically involves the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the second group of microchannel continuous flow reactors ⑤ is set to -10°C.

[0074] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0075] Example 7

[0076] This case specifically involves the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the second group of microchannel continuous flow reactors ⑤ is set to 0°C.

[0077] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0078] Example 8

[0079] This case is specifically about preparing indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the third group of microchannel continuous flow reactor ⑦ is set to 15°C.

[0080] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0081] Example 9

[0082] This case is specifically about preparing indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the third group of microchannel continuous flow reactor ⑦ is set to 35°C.

[0083] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0084] Example 10

[0085] This case is specifically about preparing indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that the temperature of the third group of microchannel continuous flow reactor ⑦ is set to 45°C.

[0086] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0087] Embodiment 11

[0088] This case specifically involves the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that: the retention time of the mixed material in S2 in the second group of microchannel continuous flow reactors ⑤ is 2 min; the flow rate of the n-butyl lithium dilute solution is set to 30 mL / min; the retention time of the mixed material in S3 in the third group of microchannel continuous flow reactors ⑦ is 40 s.

[0089] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0090] Example 12

[0091] This case specifically involves the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that: the retention time of the mixed material in S2 in the second group of microchannel continuous flow reactors ⑤ is 100 s; the flow rate of the n-butyl lithium dilute solution is set to 40 mL / min; the retention time of the mixed material in S3 in the third group of microchannel continuous flow reactors ⑦ is 35 s.

[0092] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0093] Embodiment 13

[0094] This case specifically involves the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that: the retention time of the mixed material in S1 (if there are two groups of materials, the flow rates are set to 20 mL / min and 10 mL / min; if there are mixed materials, the flow rate is set to 30 mL / min) in the first group of microchannel continuous flow reactors ③ is 120 s; the retention time of the mixed material in S2 in the second group of microchannel continuous flow reactors ⑤ is 120 s; the retention time of the mixed material in S3 in the third group of microchannel continuous flow reactors ⑦ is 40 s.

[0095] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0096] Embodiment 14

[0097] This case is specifically about the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that: DMF solution in S3 is prepared by dissolving anhydrous DMF (8 mL, 0.1 mol) in 92 mL of anhydrous tetrahydrofuran solution, mixing evenly, and preparing a 1 M DMF tetrahydrofuran solution. The flow rate of the DMF tetrahydrofuran solution is set to 20 mL / min; the retention time of the mixed material in S3 in the third group of microchannel continuous flow reactor ⑦ is 40 s.

[0098] That is, n in Example 2-13(原料) :n (碱) :n (nBuLi) :n (亲核试剂) =1:1:2:2, and in this case n (原料) :n (碱) :n (nBuLi) :n (亲核试剂) =1:1:2:1.

[0099] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0100] Embodiment 15

[0101] This case specifically involves the preparation of indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 2, except that: Preparation of DMF solution in S3: Dissolve anhydrous DMF (31 mL, 0.4 mol) in 70 mL of anhydrous tetrahydrofuran solution, mix well, and prepare a 1 M DMF tetrahydrofuran solution.

[0102] That is, n in Example 2-13 (原料) :n (碱) :n (nBuLi) :n (亲核试剂) =1:1:2:2, and in this case n (原料) :n (碱) :n (nBuLi) :n (亲核试剂) =1:1:2:4.

[0103] The product yield of this case is shown in Table 1. The peak positions of the product H NMR and C NMR are the same as those in Example 1.

[0104] The reaction conditions of the above Examples 1-15 and the yield of the product indole-5-carboxaldehyde are shown in Table 1.

[0105] Table 1 Product indole-5-carboxaldehyde yield under different reaction conditions of Examples 1-15

[0106]

[0107] As can be seen from Table 1, when the molar ratio of the brominated benzazazepine heterocyclic compound (raw material), the hydrogenation reagent (base), the debromination reagent (nBuLi), and the amide compound (nucleophilic reagent) is 1:1:2:2-4, the reaction temperature for the first reaction in the first group of microchannel continuous flow reactors is preferably 25°C-60°C, and the residence time is preferably 120 seconds-180 seconds; the reaction temperature for the second reaction in the second group of microchannel continuous flow reactors is preferably minus 30°C-minus 20°C, and the residence time is preferably 100 seconds-150 seconds; the reaction temperature for the third reaction in the third group of microchannel continuous flow reactors is preferably 15°C-45°C, and the residence time is preferably 35 seconds-50 seconds, and the yield of the product acylated substituted benzazazepine heterocyclic compound (the product indole-5-carboxaldehyde in Example 2-15) is above 90%, even as high as 99%.

[0108] Example 16

[0109] This case specifically involves the preparation of carbazole-3-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 3-bromocarbazole (amount: 24.4 g, 0.1 mol), the nucleophilic reagent is DMF (amount: 31 mL, 0.4 mol), and the product is carbazole-3-carboxaldehyde with a yield of 97%.

[0110] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ10.10(s,1H),8.61(s,1H),8.56(s,1H),8.13(d,J=8. 0Hz,1H),7.98(dd,J=8.4,1.6Hz,1H),7.52–7.47(m,3H),7.36–7.26(m,1H);

[0111] 13 C NMR (100MHz, CDCl3): δ192.03,143.33,140.00,129.07,127.34,126.97,124.11,123.56,123.22,120.76,120.73,111.17,110.97.

[0112] Embodiment 17

[0113] This case specifically involves the preparation of 8-methoxy-9H-carbazole-3-carbaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 8-methoxy-3-bromocarbazole (CAS No. 1916473-46-5, dosage: 27.5 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 8-methoxy-9H-carbazole-3-carbaldehyde with a yield of 87%.

[0114] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (500MHz, CDCl3): δ = 4.03 (s, 3H), 6.97 (d, J = 7.9Hz, 1H), 7.25 (t, J = 7.9Hz, 1H), 7.53 (d, J = 8.5Hz, 1H), 7. 73(d,J=7.9Hz,1H),7.98(dd,J=8.5,1.6Hz,1H),8.59(d,J=0.6Hz,1H),8.62(br.s,1H),10.10(s,1H)ppm.;

[0115] 13 C NMR and DEPT (125MHz, CDCl3): δ = 55.75, 107.07, 111.40, 113.14, 121.35, 123.97, 124.37, 124.70, 127.17, 129.22, 130.42, 142.95, 145.97, 192.06.

[0116] Embodiment 18

[0117] This case specifically involves the preparation of 1-methyl-9H-carbazole-3-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that of Example 15, except that the raw material is 1-methyl-3-bromo-carbazole (amount: 25.8 g, 0.1 mol, which is synthesized by the method of CN113480470A, using the corresponding monosubstituted diphenylamine as the starting material, first ring-closing and then brominating, or using the corresponding monosubstituted carbazole to directly bromine at the 3-position with NBS "Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2" [J], Bioorganic & Medicinal Chemistry Letters, 2012, 22 (1), P363-366), the nucleophile is DMF (amount: 31 mL, 0.4 mol), and the product is 1-methyl-9H-carbazole-3-carboxaldehyde with a yield of 91%.

[0118] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (500MHz, CDCl3): δ=2.62(s,3H,CH3),7.32(m,1H),7.48(br,1H),7.51(br,1H),7.80(br s,1H),8.12(br,1H),8.35(br s,1H),8.45(d,J=1.0Hz,1H),10.07(s,1H);

[0119] 13 C NMR (125MHz, CDCl3): δ=16.8,111.2,120.4,120.78,120.80,122.5,123.0,123.8,126.8,127.0,129.4,139.9,142.9,192.1.

[0120] Embodiment 19

[0121] This case specifically involves the preparation of 1,7-dimethyl-9H-carbazole-3-carbaldehyde by microchannel continuous flow. The preparation process is the same as that of Example 15, except that the raw material is 1,7-dimethyl-3-bromo-carbazole (dosage: 27.3 g, 0.1 mol, which is synthesized using the CN113480470A method, using the corresponding disubstituted diphenylamine as the starting material, first ring-closing and then brominating, or using the corresponding disubstituted carbazole to directly bromine at the 3-position with NBS "Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2" [J], Bioorganic & Medicinal Chemistry Letters, 2012, 22 (1), P363-366), the nucleophile is DMF (dosage: 31 mL, 0.4 mol), and the product is 1,7-dimethyl-9H-carbazole-3-carbaldehyde with a yield of 97%.

[0122] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (500MHz, CDCl3): δ = 2.56 (s, 3H), 2.61 (s, 3H), 7.14 (br d, J = 8.0Hz, 1H), 7.30 (br s, 1H), 7.77 (br s, 1H), 8.00 (d, J = 7.9Hz, 1H), 8.26 (br s,1H,NH),8.41(br s,1H),10.1(s,1H);

[0123] 13 C NMR (125MHz, CDCl3): δ = 16.7, 22.1, 111.3, 120.2, 120.4, 121.4, 122.1, 122.3, 123.1, 126.7, 129.3, 137.1, 140.3, 142.8, 192.1.

[0124] Embodiment 20

[0125] This case specifically involves the preparation of 1,6-dimethyl-9H-carbazole-3-carbaldehyde by microchannel continuous flow. The preparation process is the same as that of Example 15, except that the raw material is 1,6-dimethyl-3-bromo-carbazole (dosage: 27.3 g, 0.1 mol, which is synthesized using the CN113480470A method, using the corresponding disubstituted diphenylamine as the starting material, first ring-closing and then brominating, or using the corresponding disubstituted carbazole to directly bromine at the 3-position with NBS "Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2" [J], Bioorganic & Medicinal Chemistry Letters, 2012, 22 (1), P363-366), the nucleophile is DMF (dosage: 31 mL, 0.4 mol), and the product is 1,6-dimethyl-9H-carbazole-3-carbaldehyde with a yield of 91%.

[0126] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (500MHz, CDCl3): δ = 2.56 (s, 3H), 2.61 (s, 3H), 7.30 (m, 1H), 7.40 (d, J = 7.8Hz, 1H), 7.78 (br s, 1H), 7.91 (brs, 1H), 8.29 (br s, 1H, NH), 8.42 (br s,1H),10.07(s,1H);

[0127] 13 C NMR (125MHz, CDCl3): δ = 16.7, 21.5, 110.9, 120.3, 120.7, 122.6, 122.8, 123.9, 126.8, 128.1, 129.2, 130.3, 138.0, 143.1, 192.1.

[0128] Embodiment 21

[0129] This case specifically involves the preparation of 7-methoxy-9H-carbazole-3-carbaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 7-methoxy-3-bromo-carbazole (CAS No. 1353492-63-3, dosage: 28.9 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 7-methoxy-9H-carbazole-3-carbaldehyde with a yield of 93%.

[0130] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (500MHz, acetone-d6): δ = 2.62 (s, 3H), 3.88 (s, 3H), 6.90 (m, 1H), 7.08 (d, J = 2.2Hz, 1H), 7.69 (brs, 1H), 8.09 (d, J = 8.5Hz, 1H), 8.42 (br s,1H),10.03(s,1H),10.65(br,1H,NH);

[0131] 13 C NMR (125MHz, acetone-d6): δ = 17.6, 56.5, 96.8, 110.7, 118.7, 122.1, 122.5, 122.9, 124.6, 126.9, 131.1, 143.8, 144.8, 161.3, 192.8.

[0132] Embodiment 22

[0133] This case specifically involves the preparation of 6-methoxy-9H-carbazole-3-carbaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 3-bromo-6-methoxy-9H-carbazole (CAS No. 200289-73-2, dosage: 28.9 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 6-methoxy-9H-carbazole-3-carbaldehyde with a yield of 87%.

[0134] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (500MHz, CDCl3 / DMSO-d6, 9:1): δ = 2.55 (s, 3H), 3.85 (s, 3H), 7.00 (m, 1H), 7.39 (d, J = 8.5Hz, 1H), 7.49 (d, J = 2.5Hz, 1H), 7.64 (br s, 1H), 8.31 (br s,1H),9.94(s,1H),10.78(br s,1H,NH);

[0135] 13C NMR (125MHz, CDCl3 / DMSO-d6, 9:1): δ=16.4,55.2,102.2,111.8,115.0,120.4,121.8,122.0,123.2,125.4,127.5,134.8,143.4,153.5,191.3.

[0136] Embodiment 23

[0137] This case specifically involves the preparation of 6,7-dimethoxy-9H-carbazole-3-carbaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 6,7-dimethoxy-3-bromo-carbazole (amount: 32.0 g, 0.1 mol), the nucleophilic reagent is DMF (amount: 31 mL, 0.4 mol), and the product is 6,7-dimethoxy-9H-carbazole-3-carbaldehyde with a yield of 83%.

[0138] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (500MHz, CDCl3): δ = 2.59 (s, 3H), 3.98 (s, 3H), 4.02 (s, 3H), 7.02 (s, 1H), 7.55 (s, 1H), 7.71 (br s, 1H), 8.23 ​​(br s, 1H, NH), 8.34 (br s,1H),10.06(s,1H);

[0139] 13 C NMR (125MHz, CDCl3): δ=16.7,56.2,56.5,94.7,102.7,115.9,120.1,121.4,123.3,125.7,129.2,134.5,142.6,145.4,150.0,192.2.

[0140] Embodiment 24

[0141] This case specifically involves the preparation of indole-4-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 4-bromoindole (amount: 19.6 g, 0.1 mol), the nucleophilic reagent is DMF (amount: 31 mL, 0.4 mol), and the product is indole-4-carboxaldehyde with a yield of 91%.

[0142] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows: 1 HNMR (400MHz, CDCl3): δ = 7.3-7.45 (m, 3H), 7.6-7.7 (m, 2H), 8.65 (br s, 1H), 10.4 (s, 1H).

[0143] Embodiment 25

[0144] This case specifically involves the preparation of indole-6-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 6-bromoindole (amount: 19.6 g, 0.1 mol), the nucleophilic reagent is DMF (amount: 31 mL, 0.4 mol), and the product is indole-6-carboxaldehyde with a yield of 95%.

[0145] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows: 1 NMR (400MHz, CDCl3): δ = 6.64 (br s, 1H), 7.46 (m, 1H), 7.65 (d, 1H, J = 8.1), 7.74 (d, 1H, J = 8.1), 7.96 (s, 1H), 8.8 (br s, 1), 10.0 (s, 1H).

[0146] Embodiment 26

[0147] This case specifically involves the preparation of indole-7-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 7-bromoindole (amount: 19.6 g, 0.1 mol), the nucleophilic reagent is DMF (amount: 31 mL, 0.4 mol), and the product is indole-7-carboxaldehyde with a yield of 93%.

[0148] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = 6.61 (m, 1H), 7.24 (t, J = 7.5, 1H), 7.32 (m, 1H), 7.62 (d, J = 7.2, 1H), 7.92 (d, J = 7.9, 1H).

[0149] Embodiment 27

[0150] This case specifically involves the preparation of 6-fluoro-indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 6-fluoro-5-bromoindole (CAS No. 434960-42-6, dosage: 21.2 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 6-fluoro-indole-5-carboxaldehyde with a yield of 85%.

[0151] The product in this case was tested by nuclear magnetic resonance hydrogen spectrum, carbon spectrum and fluorine atom, and the results are as follows: 1H NMR (400MHz, DMSO-d6): δ = 11.60 (s, 1H), 10.16 (s, 1H), 8.06 (d, J = 6.8Hz, 1H,), 7.47 (t, J = 3.0Hz, 1H,), 7.28 (d, J = 12.0Hz, 1H,), 6.61 (s, 1H);

[0152] 13 C NMR (100MHz, DMSO-d6): δ = 188.2 (d, J CF =5Hz),160.2(d,J CF =246Hz),139.7(d,J CF =13Hz),128.8(d,J CF =3Hz),124.9,123.2(d,J CF =4Hz),117.9(d,J CF =11Hz),103.7,98.4(d,J CF =25Hz);

[0153] 19 F NMR (DMSO-d6): δ=130.24.

[0154] Embodiment 28

[0155] This case specifically involves the preparation of 7-fluoro-indole-6-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 7-fluoro-6-bromoindole (CAS No. 936901-94-9, dosage: 21.2 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 7-fluoro-indole-6-carboxaldehyde with a yield of 81%.

[0156] The product in this case was tested by nuclear magnetic resonance hydrogen spectrum, carbon spectrum and fluorine atom, and the results are as follows: 1 H NMR (400MHz, DMSO-d6): δ = 10.28 (s, 1H), 7.67–7.34 (m, 2H), 7.41–7.37 (m, 1H), 6.59 (s, 1H);

[0157] 13 C NMR (100MHz, DMSO-d6): δ = 187.3 (d, 3JCF = 7Hz), 152.7 (d, J CF =259Hz),137.0(d,J CF =8Hz),131.6,123.2(d,J CF =11Hz),117.9,117.0(d,J CF=3Hz),116.5(d,J CF =3Hz),103.7(d,J CF =1Hz);

[0158] 19 F NMR (DMSO-d6): δ=140.48.

[0159] Embodiment 29

[0160] This case specifically involves the preparation of 3-methyl-indole-7-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 3-methyl-7-bromoindole (CAS No. 86915-22-2, dosage: 21.0 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 3-methyl-indole-7-carboxaldehyde with a yield of 92%.

[0161] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ=10.12(s,1H),9.85(s,1H),7.89(d,J=7.8Hz,1H),7.65( d,J=8.1Hz,1H),7.25(d,J=7.6Hz,1H),7.12–7.09(m,1H),2.37(d,J=1.1Hz,3H).

[0162] Embodiment 30

[0163] This case specifically involves the preparation of 3-ethyl-indole-7-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 3-ethyl-7-bromoindole (CAS No. 1360962-55-5, dosage: 22.4 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 3-ethyl-indole-7-carboxaldehyde with a yield of 96%.

[0164] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = 10.12 (s, 1H), 9.87 (s, 1H), 7.92 (d, J = 7.8Hz, 1H), 7.65 (d, J = 7.3Hz, 1H), 7.26 (d, J = 7.5Hz, 1H), 7.14-7.10 (m, 1H), 2.83 (q, J = 7.5Hz, 2H), 1.35 (t, J = 7.5Hz, 3H).

[0165] Embodiment 31

[0166] This case specifically involves the preparation of 3-chloro-indole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 3-chloro-5-bromoindole (CAS No. 1388073-38-8, dosage: 17.9 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 3-chloro-indole-5-carboxaldehyde with a yield of 86%.

[0167] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = 7.31 (s, 2H), 4.45 (bs, 2H);

[0168] 13 C NMR (100MHz, CDCl3): δ=139.4, 130.2, 120.0, 107.9.

[0169] Embodiment 32

[0170] This case specifically involves the preparation of 5-benzoyl indole by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 5-bromoindole (dosage: 19.6 g, 0.1 mol), the nucleophile is N-methoxy-N-methyl-benzamide (dosage: 66 g, 0.4 mol), and the product is 5-benzoyl indole with a yield of 97%.

[0171] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = 8.85 (bs, NH, 1H), 8.14 (s, 1H), 7.86-7.77 (m, 3H), 7 .61-7.55(m,1H),7.52-7.42(m,3H),7.31-7.29(m,1H),6.69-6.60(m,1H);

[0172] 13 C NMR (100MHz, CDCl3): δ=197.7,139.0,138.4,131.7,130.0,129.6,128.2,127.2,125.9,125.4,124.2,111.2,104.2.

[0173] Embodiment 33

[0174] This case specifically involves the preparation of 7-benzoyl indole by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 7-bromoindole (dosage: 19.6 g, 0.1 mol), the nucleophile is N-methoxy-N-methyl-benzamide (dosage: 66 g, 0.4 mol), and the product is 7-benzoyl indole with a yield of 91%.

[0175] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = 9.79 (s, 1H), 7.90 (d, J = 7.6Hz, 1H), 7.80 (d, J = 7.2Hz, 1H), 7.53-7.39 (m, 5H), 7.25-7.21 (m, 2H), 6.74 (d, J = 3.2Hz, 1H);

[0176] 13 C NMR (100MHz, CDCl3): δ=189.0,142.4,136.1,131.8,131.4,130.2,128.7,127.8,126.3,124.8,122.2,120.2,104.

[0177] Embodiment 34

[0178] This case specifically involves the preparation of 5-acetylindole by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 5-bromoindole (dosage: 19.6 g, 0.1 mol), the nucleophile is N-methoxy-N-methyl-acetamide (dosage: 41.2 g, 0.4 mol), and the product is 5-acetylindole with a yield of 87%.

[0179] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ=8.78(s,1H),8.43–8.28(m,1H),7.88(dd,J=8.6,1.7Hz,1 H),7.42(dd,J=8.6,0.9Hz,1H),7.26(s,1H),6.67(m,1H),2.68(d,J=2.2Hz,3H);

[0180] 13 C NMR (101MHz, CDCl3): δ = 198.9, 138.7, 130.0, 127.5, 126.0, 123.3, 122.3, 111.2, 104.3, 26.8.

[0181] Embodiment 35

[0182] This case specifically involves the preparation of (2S)-4-[(3-tert-butyldimethylsilyl)-2-(ethoxyformamido)-1-oxopropyl]-1H-indole by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 4-bromoindole (amount: 19.6 g, 0.1 mol), the nucleophile is N-methyl-N-methoxy-[(2S)-O-(tert-butyldimethylsilyl)-N'-(ethoxyformyl)]propionamide (amount: 33.4 g, 0.2 mol), and the product is (2S)-4-[(3-tert-butyldimethylsilyl)-2-(ethoxyformamido)-1-oxopropyl]-1H-indole with a yield of 87%.

[0183] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = -0.21 (s, 3H), -0.19 (s, 3H), 0.75 (s, 9H), 1.23 (t, J = 7.1Hz, 3H), 3.97 (d, J = 2Hz, 2H), 4.18 (q ,J=7.1Hz,2H),5.52(m,1H),6.0(d,J=7.1Hz,1H,),7.2-7(m,3H),7.6(d,J=6.2Hz,1H),7.7(d,J=6.1Hz,1H),8.8(br s,1H).

[0184] Embodiment 36

[0185] This case specifically involves the preparation of 1H-benzimidazole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 5-bromobenzimidazole (CAS No. 4887-88-1, dosage: 19.5 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 1H-benzimidazole-5-carboxaldehyde with a yield of 86%.

[0186] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = 7.55 (d, J = 8.4, 1H), 7.65 (m, 1H), 8.01 (br s, 1H), 8.24 (s, 1H), 9.85 (s, 1H,);

[0187] 13 C NMR (100MHz, CDCl3): δ=116.3, 120.5, 124.5, 133.1, 139.7, 142.8, 145.9, 194.0.

[0188] Embodiment 37

[0189] This case specifically involves the preparation of 1H-benzimidazole-4-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 4-bromobenzimidazole (CAS No. 83741-35-9, dosage: 19.5 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 1H-benzimidazole-4-carboxaldehyde with a yield of 80%.

[0190] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (300MHz, DMSO-d6): δ = 10.24 (s, 1H), 8.33 (s, 1H), 8.00 (dd, J = 8.0, 1.0Hz, 1H), 7.83 (dd, J = 7.4, 1.0Hz, 1H), 7.40 (dd, J = 8.0, 7.4Hz, 1H);

[0191] 13 C NMR (75MHz, DMSO) δ191.7,144.2,142.5,127.0,124.6,122.2,121.4.

[0192] Embodiment 38

[0193] This case specifically involves the preparation of 1H-indazole-7-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 7-bromo-1H-indazole (CAS No. 53857-58-2, dosage: 19.5 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 1H-indazole-7-carboxaldehyde with a yield of 83%.

[0194] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum and carbon spectrum, and the results are as follows: 1 H NMR (300MHz, CDCl3): δ = 12.02 (s, 1H), 10.15 (s, 1H), 8.19 (s, 1H), 8.05 (dd, J = 8.0, 0.9Hz, 1H), 7.85 (dd, J = 7.1, 0.9Hz, 1H), 7.31 (dd, J = 8.1, 7.1Hz, 1H);

[0195] 13 C NMR (75MHz, CDCl3) δ192.2,136.7,134.9,133.2,128.4,124.4,120.7,120.4.

[0196] Embodiment 39

[0197] This case specifically involves the preparation of 1H-indazole-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 5-bromo-1H-indazole (CAS No. 53857-57-1, dosage: 19.5 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 1H-indazole-5-carboxaldehyde with a yield of 88%.

[0198] The product of this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows: 1 H NMR (400MHz, CDCl3): δ = 10.54 (br s, 1H, NH), 10.07 (s, 1H), 8.32 (s, 1H), 8.27 (s, 1H), 7.99 (d, J = 9.0Hz, 1H), 7.62 (d, J = 9.0Hz, 1H).

[0199] Embodiment 40

[0200] This case specifically involves the preparation of 2-oxoindoline-5-carboxaldehyde by microchannel continuous flow. The preparation process is the same as that in Example 15, except that the raw material is 5-bromoindoline (CAS No. 20870-78-4, dosage: 21.1 g, 0.1 mol), the nucleophilic reagent is DMF (dosage: 31 mL, 0.4 mol), and the product is 2-oxoindoline-5-carboxaldehyde with a yield of 92%.

[0201] The product in this case was tested by nuclear magnetic resonance hydrogen spectrum, and the results are as follows 1 H NMR (500MHz, DMSO-d6): δ = 7.83 (d, J = 1.5Hz, 1H), 7.69-7.65 (m, 2H), 6.85 (dd, J = 17.6, 10.9Hz, 1H), 5.97 (dd, J=17.6, 0.9Hz, 1H), 5.38 (dd, J=10.9, 0.8Hz, 1H), 4.37 (s, 2H).

[0202] The raw materials and products of Examples 15-40 above are shown in Table 2.

[0203] Table 2 Raw materials and corresponding products and yields of Examples 15-40

[0204]

[0205]

[0206]

[0207] As can be seen from Table 2, the method of the present invention can introduce an acyl group onto the benzene ring of a brominated benzazazepine heterocyclic compound, and the yield of the corresponding acylated product is above 80%.

[0208] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound, characterized in that: The steps include: S1, mixing a solution containing a brominated benzene nitrogen heterocyclic compound with a solution containing a hydrogen extraction agent to perform a first reaction to remove active hydrogen from the nitrogen heterocyclic ring to obtain a first material; S2, mixing the first material with a solution containing a debromination agent to perform a second reaction to obtain a second material; S3, allowing the second material to undergo a third reaction with a solution containing an amide compound, so that a nucleophilic substitution reaction occurs at the substitution position of the original bromine on the aromatic group of the brominated benzazazepine heterocyclic compound to obtain an acylated substituent, and after the reaction is completed, the reaction is quenched, and post-processing is performed to obtain an acylated substituted benzazazepine heterocyclic compound; The brominated benzazazepine heterocyclic compound is selected from the group consisting of brominated indole compounds, brominated benzimidazole compounds, brominated indazole compounds, brominated indoleline compounds, and brominated carbazole compounds; The hydrogen-extraction reagent is an aminoalkylsilane compound; and the debromination reagent is a C1-C20 normal or isomeric alkyl lithium.

2. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 1, characterized in that: The brominated benzene nitrogen heterocyclic compound has the following chemical structure: Wherein, X is selected from nitrogen atom or carbon atom; when X is nitrogen atom, R1 is absent; when X is carbon atom, R1 is selected from one of hydrogen atom, C1-C6 normal or isomeric alkyl, chlorine atom; R5 is selected from halogen atom; R2 and R3 are each selected from a hydrogen atom, a C1-C6 normal or isomeric alkoxy group, or a C1-C6 normal or isomeric alkyl group, and R2 and R3 are the same or different; R4 is selected from a hydrogen atom, a C1-C6 normal or isomeric alkoxy group; R6 and R7 are each selected from a hydrogen atom, a C1-C6 normal or isomeric alkyl group, and R6 and R7 are the same or different; The aminoalkylsilane compound is selected from sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, and lithium bis(trimethylsilyl)amide; The alkyl lithium is n-butyl lithium; The amide compound is selected from one of N,N-dimethylformamide, N,N-dimethylacetamide, N-methoxy-N-methyl-benzamide, N-methoxy-N-methyl-acetamide, and N-methyl-N-methoxy-[(2S)-O-(tert-butyldimethylsilyl)-N'-(ethoxyformyl)]propionamide.

3. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 2, characterized in that: The brominated benzazazepine heterocyclic compound is selected from 4-bromoindole, 5-bromoindole, 6-bromoindole, 7-bromoindole, 6-fluoro-5-bromoindole, 7-fluoro-6-bromoindole, 3-methyl-7-bromoindole, 3-ethyl-7-bromoindole, 3-chloro-7-bromoindole, 3-chloro-5-bromoindole, 3-bromocarbazole, 8-methoxy-3-bromocarbazole, 1-methyl-3-bromo-carbazole, 1,7-dimethyl-3-bromo-carbazole, 1,6-dimethyl-3-bromo-carbazole, 7-methoxy-3-bromo-carbazole, 3-bromo-6-methoxy-carbazole, 6,7-dimethoxy-3-bromo-carbazole, 4-bromobenzimidazole, 5-bromobenzimidazole, 7-bromo-indazole, 5-bromo-indole, 5-bromo-indoline, and 5-bromo-2-oxoindoline.

4. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to any one of claims 1 to 3, characterized in that: The first reaction is carried out in a first group of microchannel continuous flow reactors, the second reaction is carried out in a second group of microchannel continuous flow reactors, and the third reaction is carried out in a third group of microchannel continuous flow reactors; the first group of microchannel continuous flow reactors, the second group of microchannel continuous flow reactors, and the third group of microchannel continuous flow reactors are connected to each other by microchannels; and each raw material is pumped into the reactor of each reaction stage in an injection pump.

5. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 4, characterized in that: The first group of microchannel continuous flow reactors consists of three glass chips, the second group of microchannel continuous flow reactors consists of five glass chips, and the third group of microchannel continuous flow reactors consists of two glass chips, and each glass chip has a liquid holding capacity of 20 mL.

6. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 5, characterized in that: The reaction temperature of the first reaction is in the range of 23°C-65°C, and the residence time is in the range of 100 seconds-200 seconds; the reaction temperature of the second reaction is in the range of minus 35°C-minus 10°C, and the residence time is in the range of 80 seconds-180 seconds; the reaction temperature of the third reaction is in the range of 12°C-50°C, and the residence time is in the range of 30 seconds-55 seconds.

7. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 6, characterized in that: The reaction temperature of the first reaction is 25°C-60°C, and the residence time is 120 seconds-180 seconds; the reaction temperature of the second reaction is minus 30°C-minus 20°C, and the residence time is 100 seconds-150 seconds; the reaction temperature of the third reaction is 15°C-45°C, and the residence time is 35 seconds-50 seconds.

8. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 4, characterized in that: The molar ratio of the brominated benzazine heterocyclic compound, the hydrogenation reagent, the debromination reagent, and the amide compound is 1:1:2:2-4.

9. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 4, characterized in that: The solvents in the solution containing brominated benzazine heterocyclic compounds, the solution containing hydrogen extraction reagents, the solution containing debromination reagents, and the solution containing amide compounds are respectively anhydrous tetrahydrofuran or n-hexane; The concentration of the solution containing the brominated benzazine heterocyclic compound is 0.8-1.5 mol / L, and the flow rate in the reactor is 10-30 mL / min; The concentration of the solution containing the hydrogen extraction agent is 0.8-2 mol / L, and the flow rate in the reactor is 20-40 mL / min; The concentration of the solution containing the debromination agent is 0.8-2 mol / L, and the flow rate in the reactor is 20-40 mL / min; The concentration of the solution containing amide compounds is 1.5-5 mol / L, and the flow rate in the reactor is 10-30 mL / min.

10. The method for debromination and acylation of the aromatic group of a brominated benzazazepine heterocyclic compound according to claim 4, characterized in that: The post-treatment includes the following operations: cooling the third material collected from the third group of microchannel continuous flow reactors to below 5° C., adding phosphoric acid aqueous solution to quench the reaction, extracting with acid ester solvents, combining organic phases, washing, drying, desolventizing, and recrystallizing.

Citation Information

Cited By

  • Method for aryl debromination and acylation of brominated benzazepine compound

    WO2026044951A1